{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:28:33Z","timestamp":1786512513965,"version":"build-2736575974"},"reference-count":86,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Type VII collagen (Col VII) is a key component of the anchoring fibrils at the dermal-epidermal junction (DEJ). It plays a crucial role in maintaining stable adhesion between the epidermis and dermis, promoting wound re-epithelialization, and ensuring the structural integrity of the skin following repair. With advancements in genetic engineering, synthetic biology, and recombinant protein expression technologies, recombinant humanized type VII collagen (rhCol VII) has gradually emerged as a novel functional biomaterial of interest in the fields of skin repair and regenerative medicine. Compared with traditional type I and type III collagen materials, the potential advantages of rhCol VII lie in its excellent safety profile, scalability for industrial production, and its potential structural and functional targeting of the DEJ, which may offer new insights into restoring interface stability following wound repair. This review summarizes the molecular structure, biological functions, and recent therapeutic research progress of Col VII, as well as the application prospects of rhCol VII in chronic wounds, post-aesthetic surgery barrier damage, and tissue-engineered skin. It also discusses the challenges that remain to be addressed in material development and clinical translation, with the aim of providing a reference for further research on rhCol VII-based skin repair materials.<\/jats:p>","DOI":"10.3389\/fmed.2026.1912442","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T04:46:50Z","timestamp":1786510010000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Recombinant humanized type VII collagen for skin repair and regeneration: prospects for reconstructing the dermal-epidermal junction"],"prefix":"10.3389","volume":"13","author":[{"given":"Yanyan","family":"Lin","sequence":"first","affiliation":[{"name":"School of Industry, Shanxi Medical University, Jinzhong","place":["Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zheng","sequence":"additional","affiliation":[{"name":"School of Nursing, Shanxi Medical University, Jinzhong","place":["Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobin","family":"Lan","sequence":"additional","affiliation":[{"name":"Shanxi Key Laboratory of Functional Proteins, Shanxi Jinbo Bio-Pharmaceutical Co., Ltd., Taiyuan","place":["Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1111\/j.1600-0625.2008.00786.x","article-title":"The skin: an indispensable barrier","volume":"17","author":"Proksch","year":"2008","journal-title":"Exp Dermatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.3390\/cells12232745","article-title":"Skin barrier function: the interplay of physical, chemical, and immunologic properties","volume":"12","author":"Baker","year":"2023","journal-title":"Cells"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/jidsymp.2009.5","article-title":"Possible involvement of basement membrane damage in skin photoaging","volume":"14","author":"Amano","year":"2009","journal-title":"J Investig Dermatol Symp Proc."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.3390\/ijms22083974","article-title":"Inflammatory molecules associated with ultraviolet radiation-mediated skin aging","volume":"22","author":"Ansary","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1007\/s00018-016-2268-0","article-title":"Transition from inflammation to proliferation: a critical step during wound healing","volume":"73","author":"Land\u00e9n NX Li","year":"2016","journal-title":"Cell Mol Life Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.3390\/biom12111659","article-title":"Macrophages in skin wounds: functions and therapeutic potential","volume":"12","author":"Sim","year":"2022","journal-title":"Biomolecules"},{"key":"B7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/bioengineering8050063","article-title":"Collagen in wound healing","volume":"8","author":"Mathew-Steiner","year":"2021","journal-title":"Bioengineering (Basel)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"101530","DOI":"10.1016\/j.jbc.2021.101530","article-title":"The interplay of fibroblasts, the extracellular matrix, and inflammation in scar formation","volume":"298","author":"Moretti","year":"2022","journal-title":"J Biol Chem."},{"key":"B9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1089\/wound.2013.0485","article-title":"Extracellular matrix reorganization during wound healing and its impact on abnormal scarring","volume":"4","author":"Xue","year":"2015","journal-title":"Adv Wound Care."},{"key":"B10","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/bip.22486","article-title":"Review collagen-based biomaterials for wound healing","volume":"101","author":"Chattopadhyay","year":"2014","journal-title":"Biopolymers."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.3390\/ma3031863","article-title":"Collagen-based biomaterials for tissue engineering applications","volume":"3","author":"Parenteau-Bareil","year":"2010","journal-title":"Materials (Basel)."},{"key":"B12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.26502\/fccm.92920302","article-title":"Regulation of collagen I and collagen III in tissue injury and regeneration","volume":"7","author":"Singh","year":"2023","journal-title":"Cardiol Cardiovasc Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.jid.2024.08.013","article-title":"Type III collagen regulates matrix architecture and mechanosensing during wound healing","volume":"145","author":"Stewart","year":"2025","journal-title":"J Invest Dermatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3390\/bioengineering8110148","article-title":"The importance of mimicking dermal-epidermal junction for skin tissue engineering: a review","volume":"8","author":"Aleemardani","year":"2021","journal-title":"Bioengineering (Basel)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.bioactmat.2021.10.031","article-title":"A regulatory perspective on recombinant collagen-based medical devices","volume":"12","author":"Liu","year":"2022","journal-title":"Bioact Mater."},{"key":"B16","doi-asserted-by":"publisher","first-page":"582","DOI":"10.3390\/life15040582","article-title":"Advancements in clinical utilization of recombinant human collagen: an extensive review","volume":"15","author":"Jie","year":"2025","journal-title":"Life (Basel)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/bioengineering6030056","article-title":"Sources of collagen for biomaterials in skin wound healing","volume":"6","author":"Davison-Kotler","year":"2019","journal-title":"Bioengineering (Basel)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1358246","DOI":"10.3389\/fbioe.2024.1358246","article-title":"Tissue engineering applications of recombinant human collagen: a review of recent progress","volume":"12","author":"Cao","year":"2024","journal-title":"Front Bioeng Biotechnol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1038\/mt.2013.87","article-title":"Topical application of recombinant type VII collagen incorporates into the dermal-epidermal junction and promotes wound closure","volume":"21","author":"Wang","year":"2013","journal-title":"Mol Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1074\/jbc.M108779200","article-title":"The recombinant expression of full-length type VII collagen and characterization of molecular mechanisms underlying dystrophic epidermolysis bullosa","volume":"277","author":"Chen","year":"2002","journal-title":"J Biol Chem."},{"key":"B21","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S0888-7543(05)80204-6","article-title":"PCR-based detection of two exonic polymorphisms in the human type VII collagen gene (COL7A1) at 3p21","volume":"14","author":"Christiano","year":"1992","journal-title":"1 Genomics."},{"key":"B22","doi-asserted-by":"publisher","first-page":"6931","DOI":"10.1073\/pnas.88.16.6931","article-title":"Human type VII collagen: cDNA cloning and chromosomal mapping of the gene","volume":"88","author":"Parente","year":"1991","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1111\/j.1582-4934.2009.00959.x","article-title":"Autoimmunity against type VII collagen in inflammatory bowel disease","volume":"14","author":"Hundorfean","year":"2010","journal-title":"J Cell Mol Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.bbadis.2016.10.023","article-title":"type VII collagen subdomain mutant is thermolabile and shows enhanced proteolytic degradability\u2014implications for the pathogenesis of recessive dystrophic epidermolysis bullosa?","volume":"1863","author":"Windler","year":"2017","journal-title":"Biochim Biophys Acta Mol Basis Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s12104-015-9636-9","article-title":"Chemical shift assignments of the fibronectin III like domains 7-8 of type VII collagen","volume":"10","author":"Hermsdorf","year":"2016","journal-title":"Biomol NMR Assign."},{"key":"B26","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.bbrc.2006.03.034","article-title":"High-affinity binding of the NC1 domain of collagen VII to laminin 5 and collagen IV","volume":"343","author":"Brittingham","year":"2006","journal-title":"Biochem Biophys Res Commun."},{"key":"B27","doi-asserted-by":"publisher","first-page":"21649","DOI":"10.1074\/jbc.M100180200","article-title":"The carboxyl terminus of type VII collagen mediates antiparallel dimer formation and constitutes a new antigenic epitope for epidermolysis Bullosa acquisita autoantibodies","volume":"276","author":"Chen","year":"2001","journal-title":"J Biol Chem."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.jid.2023.11.003","article-title":"Epidermal or dermal collagen VII is sufficient for skin integrity: insights to anchoring fibril homeostasis","volume":"144","author":"Conradt","year":"2024","journal-title":"J Investig Dermatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"11434","DOI":"10.1021\/bi034925d","article-title":"Procollagen VII self-assembly depends on site-specific interactions and is promoted by cleavage of the NC2 domain with procollagen C-proteinase","volume":"42","author":"Colombo","year":"2003","journal-title":"Biochemistry."},{"key":"B30","doi-asserted-by":"publisher","first-page":"26372","DOI":"10.1074\/jbc.M203247200","article-title":"Proteinases of the bone morphogenetic protein-1 family convert procollagen VII to mature anchoring fibril collagen","volume":"277","author":"Rattenholl","year":"2002","journal-title":"J Biol Chem."},{"key":"B31","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.det.2009.10.011","article-title":"Type VII collagen: the anchoring fibril protein at fault in dystrophic epidermolysis bullosa","volume":"28","author":"Chung","year":"2010","journal-title":"Dermatol Clin."},{"key":"B32","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/1523-1747.ep12365129","article-title":"Type VII collagen, anchoring fibrils, and epidermolysis bullosa","volume":"101","author":"Burgeson","year":"1993","journal-title":"J Investig Dermatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.1172\/JCI68127","article-title":"Collagen VII plays a dual role in wound healing","volume":"123","author":"Nystr\u00f6m","year":"2013","journal-title":"J Clin Invest."},{"key":"B34","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1089\/wound.2012.0406","article-title":"Critical role of transforming growth factor beta in different phases of wound healing","volume":"2","author":"Pakyari","year":"2013","journal-title":"Adv Wound Care."},{"key":"B35","doi-asserted-by":"publisher","first-page":"115513","DOI":"10.1016\/j.matdes.2026.115513","article-title":"Advances in recombinant type III collagen","volume":"262","author":"Wang","year":"2026","journal-title":"Mater Des."},{"key":"B36","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jmg.2006.045302","article-title":"Epidermolysis bullosa. II Type VII collagen mutations and phenotype-genotype correlations in the dystrophic subtypes","volume":"44","author":"Varki","year":"2007","journal-title":"J Med Genet."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s40265-023-01921-5","article-title":"Beremagene geperpavec: first approval","volume":"83","author":"Dhillon","year":"2023","journal-title":"Drugs."},{"key":"B38","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41591-022-01737-y","article-title":"In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial","volume":"28","author":"Gurevich","year":"2022","journal-title":"Nat Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa2206663","article-title":"Trial of beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa","volume":"387","author":"Guide Shireen","year":"2022","journal-title":"N Eng J Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s40257-025-00942-y","article-title":"Long-term safety and tolerability of beremagene geperpavec-svdt (B-VEC) in an open-label extension study of patients with dystrophic epidermolysis bullosa","volume":"26","author":"Marinkovich","year":"2025","journal-title":"Am J Clin Dermatol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0140-6736(25)00778-0","article-title":"Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial","volume":"406","author":"Tang","year":"2025","journal-title":"Lancet."},{"key":"B42","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/MS9.0000000000004501","article-title":"approval of prademagene zamikeracel (Zevaskyn): advancing gene therapy for recessive dystrophic epidermolysis bullosa (RDEB) patients","volume":"88","author":"Shahid","year":"2026","journal-title":"Ann Med Surg (Lond)."},{"key":"B43","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/nm1063","article-title":"Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa","volume":"10","author":"Woodley","year":"2004","journal-title":"Nat Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/mt.2008.234","article-title":"Injection of recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa","volume":"17","author":"Remington","year":"2009","journal-title":"Mol Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1046\/j.1523-1747.2003.12571.x","article-title":"Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone","volume":"121","author":"Woodley","year":"2003","journal-title":"J Invest Dermatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1038\/jid.2008.78","article-title":"Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa","volume":"128","author":"Wong","year":"2008","journal-title":"J Invest Dermatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1038\/mt.2009.144","article-title":"Mechanisms of fibroblast cell therapy for dystrophic epidermolysis bullosa: high stability of collagen VII favors long-term skin integrity","volume":"17","author":"Kern","year":"2009","journal-title":"Mol Ther."},{"key":"B48","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.jaad.2013.08.014","article-title":"A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa","volume":"69","author":"Venugopal","year":"2013","journal-title":"J Am Acad Dermatol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.jaad.2019.11.038","article-title":"Phase I\/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa","volume":"83","author":"Rashidghamat","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1172\/jci.insight.151922","article-title":"Clinical trial of ABCB5+ mesenchymal stem cells for recessive dystrophic epidermolysis bullosa","volume":"6","author":"Kiritsi","year":"2021","journal-title":"JCI Insight"},{"key":"B51","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.jcyt.2023.01.015","article-title":"ABCB5(+) mesenchymal stromal cells facilitate complete and durable wound closure in recessive dystrophic epidermolysis bullosa","volume":"25","author":"Dieter","year":"2023","journal-title":"Cytotherapy."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.20944\/preprints202305.0357.v1","article-title":"Kinetics of wound development and healing suggests a skin-stabilizing effect of allogeneic ABCB5(+) mesenchymal stromal cell treatment in recessive dystrophic epidermolysis bullosa","volume":"12","author":"Niebergall-Roth","year":"2023","journal-title":"Cells"},{"key":"B53","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa0910501","article-title":"Bone marrow transplantation for recessive dystrophic epidermolysis bullosa","volume":"363","author":"Wagner","year":"2010","journal-title":"N Engl J Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/S0140-6736(13)61897-8","article-title":"Allogeneic blood and bone marrow cells for the treatment of severe epidermolysis bullosa: repair of the extracellular matrix","volume":"382","author":"Tolar","year":"2013","journal-title":"Lancet."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1111\/bjd.17858","article-title":"Bone marrow transplant with post-transplant cyclophosphamide for recessive dystrophic epidermolysis bullosa expands the related donor pool and permits tolerance of nonhaematopoietic cellular grafts","volume":"181","author":"Ebens","year":"2019","journal-title":"Br J Dermatol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1111\/bjd.19503","article-title":"Immune tolerance of allogeneic haematopoietic cell transplantation supports donor epidermal grafting of recessive dystrophic epidermolysis bullosa chronic wounds","volume":"184","author":"Ebens","year":"2021","journal-title":"Br J Dermatol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.3390\/ijms23031732","volume":"23","author":"Mayr","year":"2022","journal-title":"Int J Mol Sci."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1016\/j.ymthe.2017.07.005","article-title":"COL7A1 Editing via CRISPR\/Cas9 in recessive dystrophic epidermolysis bullosa","volume":"25","author":"Hainzl","year":"2017","journal-title":"Mol Ther."},{"key":"B59","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.omtn.2018.06.008","volume":"12","author":"Izmiryan","year":"2018","journal-title":"Ex VivoMol Ther Nucleic Acids."},{"key":"B60","doi-asserted-by":"publisher","first-page":"812029","DOI":"10.1155\/2013\/812029","article-title":"Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita","volume":"2013","author":"Ludwig","year":"2013","journal-title":"ISRN Dermatol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.abd.2021.09.010","article-title":"Epidermolysis bullosa acquisita","volume":"97","author":"Miyamoto","year":"2022","journal-title":"An Bras Dermatol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3390\/jcm12031139","article-title":"Epidermolysis bullosa acquisita-current and emerging treatments","volume":"12","author":"Te\u0161anovi\u0107 Perkovi\u0107","year":"2023","journal-title":"J Clin Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s12079-017-0417-3","article-title":"Restoration of the basement membrane after wounding: a hallmark of young human skin altered with aging","volume":"12","author":"Fisher","year":"2018","journal-title":"J Cell Commun Signal."},{"key":"B64","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.0906-6705.2005.00316.x","article-title":"Keratinocyte-specific modulation of type VII collagen gene expression by pro-inflammatory cytokines (tumor necrosis factor-alpha and interleukin-1beta)","volume":"14","author":"Takeda","year":"2005","journal-title":"Exp Dermatol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1089\/ten.tea.2013.0160","article-title":"Superficial dermal fibroblasts enhance basement membrane and epidermal barrier formation in tissue-engineered skin: implications for treatment of skin basement membrane disorders","volume":"20","author":"Varkey","year":"2014","journal-title":"Tissue Eng Part A."},{"key":"B66","doi-asserted-by":"publisher","first-page":"151899","DOI":"10.1016\/j.ijbiomac.2026.151899","article-title":"The biosafety and efficacy of recombinant humanized type VII collagen with a triple-helical structure in acute skin repair","volume":"361","author":"Lan","year":"2026","journal-title":"Int J Biol Macromol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"4928","DOI":"10.3390\/ijms23094928","article-title":"Chronic inflammation in non-healing skin wounds and promising natural bioactive compounds treatment","volume":"23","author":"Schilrreff","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2300396","DOI":"10.1002\/adtp.202300396","article-title":"Approaches to control and monitor protease levels in chronic wounds","volume":"7","author":"Kolahreez","year":"2024","journal-title":"Adv Therap."},{"key":"B69","doi-asserted-by":"publisher","first-page":"23593","DOI":"10.1038\/s41598-024-74426-0","article-title":"Deficient functional wound closure as measured by elevated trans-epidermal water loss predicts chronic wound recurrence: an exploratory observational study","volume":"14","author":"Chattopadhyay","year":"2024","journal-title":"Sci Rep."},{"key":"B70","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1177\/21621918251382448","article-title":"High transepidermal water loss at the closed wound site marks compromised functional wound closure and associates with wound recurrence in diabetic foot ulcers: a prognostic factor study","volume":"14","author":"Schmidt","year":"2025","journal-title":"Adv Wound Care."},{"key":"B71","doi-asserted-by":"publisher","first-page":"277","DOI":"10.4103\/ds.DS-D-25-00149","article-title":"Basement membrane zone proteins in wound healing: Insights from epidermolysis bullosa models","volume":"43","author":"Trajkovic","year":"2025","journal-title":"Dermatologica Sinica."},{"key":"B72","first-page":"24","article-title":"Review of post-laser-resurfacing topical agents for improved healing and cosmesis","volume":"14","author":"Angra","year":"2021","journal-title":"J Clin Aesthet Dermatol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"e70223","DOI":"10.1111\/jocd.70223","article-title":"Evaluation of the efficacy and safety of a panthenol-enriched mask for skin barrier recovery after facial laser treatment: results of a double-blind randomized controlled study","volume":"24","author":"Gao","year":"2025","journal-title":"J Cosmet Dermatol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"e70109","DOI":"10.1111\/jocd.70109","article-title":"Split-face micro-needling study to evaluate the efficacy and consumer perception of a novel moisturization agent","volume":"24","author":"Nawaz","year":"2025","journal-title":"J Cosmet Dermatol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.bioactmat.2021.10.004","article-title":"The biological effect of recombinant humanized collagen on damaged skin induced by UV-photoaging: An in vivo study","volume":"11","author":"Wang","year":"2022","journal-title":"Bioact Mater."},{"key":"B76","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s42825-022-00103-5","article-title":"Characterization of recombinant humanized collagen type III and its influence on cell behavior and phenotype","volume":"4","author":"Wang","year":"2022","journal-title":"J Leather Sci Eng."},{"key":"B77","doi-asserted-by":"publisher","first-page":"e70226","DOI":"10.1111\/jocd.70226","article-title":"Recombinant type III humanized collagen solution for injection promotes skin repair in Chinese population: a case series","volume":"24","author":"Duan","year":"2025","journal-title":"J Cosmet Dermatol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1046\/j.1523-1747.1999.00491.x","article-title":"NC1 domain of type VII collagen binds to the beta3 chain of laminin 5 via a unique subdomain within the fibronectin-like repeats","volume":"112","author":"Chen","year":"1999","journal-title":"J Invest Dermatol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3109\/10409231003627991","article-title":"Prolyl 4-hydroxylase","volume":"45","author":"Gorres","year":"2010","journal-title":"Crit Rev Biochem Mol Biol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1146\/annurev.biochem.77.032207.120833","article-title":"Collagen structure and stability","volume":"78","author":"Shoulders","year":"2009","journal-title":"Annu Rev Biochem."},{"key":"B81","doi-asserted-by":"publisher","first-page":"107757","DOI":"10.1016\/j.biotechadv.2021.107757","article-title":"The emerging role of cellular post-translational modifications in modulating growth and productivity of recombinant Chinese hamster ovary cells","volume":"49","author":"Bryan","year":"2021","journal-title":"Biotechnol Adv."},{"key":"B82","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.3389\/fbioe.2022.880155","article-title":"Factors affecting the expression of recombinant protein and improvement strategies in Chinese hamster ovary cells","volume":"10","author":"Li","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1038\/jid.2015.291","article-title":"Intravenously administered recombinant human type VII collagen derived from Chinese hamster ovary cells reverses the disease phenotype in recessive dystrophic epidermolysis bullosa mice","volume":"135","author":"Hou","year":"2015","journal-title":"J Invest Dermatol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1042\/bst0280353","article-title":"Expression of recombinant human type I-III collagens in the yeast pichia pastoris","volume":"28","author":"Myllyharju","year":"2000","journal-title":"Biochem Soc Trans."},{"key":"B85","doi-asserted-by":"publisher","first-page":"106184","DOI":"10.1016\/j.pep.2022.106184","article-title":"Co-expression of recombinant human collagen \u03b11(III) chain with viral prolyl 4-hydroxylase in Pichia pastoris GS115","volume":"201","author":"Fang","year":"2023","journal-title":"Protein Expr Purif."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.jid.2021.09.008","article-title":"Systemic collagen VII replacement therapy for advanced recessive dystrophic epidermolysis bullosa","volume":"142","author":"Gretzmeier","year":"2022","journal-title":"J Investig Dermatol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1912442\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T04:47:01Z","timestamp":1786510021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1912442\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":86,"alternative-id":["10.3389\/fmed.2026.1912442"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1912442","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"article-number":"1912442"}}